Agentix Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Agentix Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $0 | Jul 14, 2023 |
| FY2023 | Mar 31, 2022 | $1.2K | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | $1.2K | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | $0 | Oct 7, 2021 |
| FY2018 | Aug 31, 2017 | $2.3K | Nov 13, 2018 |
| FY2017 | Aug 31, 2016 | $43.1K | Dec 18, 2017 |
| FY2016 | Aug 31, 2015 | $28.4K | Dec 12, 2016 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Aug 31, 2015 | $3.4K | Dec 16, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $0 | Jul 14, 2023 |
| FY2023 | Mar 31, 2022 | $679 | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | $679 | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | $0 | Oct 7, 2021 |
| FY2018 | Aug 31, 2017 | $893 | Nov 13, 2018 |
| FY2017 | Aug 31, 2016 | $41.8K | Dec 18, 2017 |
| FY2016 | Aug 31, 2015 | $26.3K | Dec 12, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($567.0K) | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | ($585.2K) | Jul 16, 2025 |
| FY2024 | Mar 31, 2023 | ($1.37M) | Aug 30, 2024 |
| FY2023 | Mar 31, 2022 | ($2.63M) | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | ($243.4K) | Oct 7, 2021 |
| FY2021 | May 31, 2021 | ($173.2K) | Oct 7, 2021 |
| FY2021 | Feb 28, 2021 | ($707.0K) | Oct 7, 2021 |
| FY2021 | Nov 30, 2020 | ($216.7K) | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | ($363.9K) | Oct 7, 2021 |
| FY2021 | May 31, 2020 | $0 | Oct 7, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($513.3K) | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | ($744.8K) | Jul 16, 2025 |
| FY2024 | Mar 31, 2023 | ($1.37M) | Aug 30, 2024 |
| FY2023 | Mar 31, 2022 | ($2.63M) | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | ($1.34M) | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | ($344.4K) | Oct 7, 2021 |
| FY2019 | Aug 31, 2019 | ($121.3K) | Dec 5, 2019 |
| FY2019 | Aug 31, 2018 | ($134.4K) | Dec 5, 2019 |
| FY2018 | Aug 31, 2017 | ($334.0K) | Nov 13, 2018 |
| FY2017 | Aug 31, 2016 | ($292.4K) | Dec 18, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $181.0K | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | $175.3K | Jul 16, 2025 |
| FY2024 | Mar 31, 2023 | $711.5K | Aug 30, 2024 |
| FY2023 | Mar 31, 2022 | $279.9K | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | $365.1K | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | $94.1K | Oct 7, 2021 |
| FY2017 | Aug 31, 2016 | $3.7K | Dec 18, 2017 |
| FY2016 | Aug 31, 2015 | $28.3K | Dec 12, 2016 |
| FY2015 | Aug 31, 2014 | $61.7K | Dec 16, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($125.1K) | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | ($110.4K) | Jul 16, 2025 |
| FY2024 | Mar 31, 2023 | ($88.5K) | Aug 30, 2024 |
| FY2023 | Mar 31, 2022 | ($25.2K) | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | ($421.0K) | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | ($368.8K) | Oct 7, 2021 |
| FY2019 | Aug 31, 2019 | ($62.0K) | Dec 5, 2019 |
| FY2019 | Aug 31, 2018 | ($51.6K) | Dec 5, 2019 |
| FY2018 | Aug 31, 2017 | ($76.4K) | Nov 13, 2018 |
| FY2017 | Aug 31, 2016 | ($12.6K) | Dec 18, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Aug 31, 2014 | $1.3K | Dec 16, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $100.3K | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | $106.4K | Jul 16, 2025 |
| FY2024 | Mar 31, 2023 | $261.4K | Aug 30, 2024 |
| FY2023 | Mar 31, 2022 | $16.0K | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | $51.2K | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | $292.8K | Oct 7, 2021 |
| FY2019 | Aug 31, 2019 | $93 | Dec 5, 2019 |
| FY2019 | Aug 31, 2018 | $2.3K | Dec 5, 2019 |
| FY2018 | Aug 31, 2017 | $7.1K | Nov 13, 2018 |
| FY2017 | Aug 31, 2016 | $1.3K | Dec 18, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.20M | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | $2.67M | Jul 16, 2025 |
| FY2024 | Mar 31, 2023 | $2.51M | Aug 30, 2024 |
| FY2023 | Mar 31, 2022 | $1.09M | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | $606.9K | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | $69.3K | Oct 7, 2021 |
| FY2019 | Aug 31, 2019 | $125.9K | Dec 5, 2019 |
| FY2019 | Aug 31, 2018 | $55.4K | Dec 5, 2019 |
| FY2018 | Aug 31, 2017 | $72.2K | Nov 13, 2018 |
| FY2017 | Aug 31, 2016 | $3.7K | Dec 18, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($3.10M) | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | ($2.56M) | Jul 16, 2025 |
| FY2025 | Mar 31, 2023 | ($2.25M) | Jul 16, 2025 |
| FY2024 | Mar 31, 2022 | ($1.08M) | Aug 30, 2024 |
| FY2021 | Aug 31, 2021 | ($555.7K) | Oct 7, 2021 |
| FY2021 | May 31, 2021 | ($312.3K) | Oct 7, 2021 |
| FY2023 | Mar 31, 2021 | ($220.4K) | Jul 14, 2023 |
| FY2021 | Feb 28, 2021 | ($239.1K) | Oct 7, 2021 |
| FY2021 | Nov 30, 2020 | $6.7K | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | $223.5K | Oct 7, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($6.52M) | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | ($5.95M) | Jul 16, 2025 |
| FY2024 | Mar 31, 2023 | ($5.37M) | Aug 30, 2024 |
| FY2023 | Mar 31, 2022 | ($4.00M) | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | ($1.70M) | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | ($363.9K) | Oct 7, 2021 |
| FY2019 | Aug 31, 2019 | ($44.03M) | Dec 5, 2019 |
| FY2019 | Aug 31, 2018 | ($43.90M) | Dec 5, 2019 |
| FY2018 | Aug 31, 2017 | ($1.11M) | Nov 13, 2018 |
| FY2017 | Aug 31, 2016 | ($727.9K) | Dec 18, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $12.4K | Jul 14, 2023 |
| FY2023 | Mar 31, 2022 | $145 | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | $1.8K | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | $242.8K | Oct 7, 2021 |
| FY2021 | Apr 14, 2020 | $0 | Oct 7, 2021 |
| FY2019 | Aug 31, 2018 | $2.1K | Dec 5, 2019 |
| FY2019 | Aug 31, 2017 | $3.7K | Dec 5, 2019 |
| FY2018 | Aug 31, 2016 | $619 | Nov 13, 2018 |
| FY2017 | Aug 31, 2015 | $13.2K | Dec 18, 2017 |
| FY2016 | Aug 31, 2014 | $134.8K | Dec 12, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Aug 31, 2019 | $85.0K | Dec 5, 2019 |
| FY2019 | Aug 31, 2018 | $50.0K | Dec 5, 2019 |
| FY2018 | Aug 31, 2017 | $89.0K | Nov 13, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 16, 2025 |
| FY2016 | Aug 31, 2016 | 0 | Dec 12, 2016 |
| FY2016 | Aug 31, 2015 | 0 | Dec 12, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 40.07M | Jul 16, 2025 |
| FY2025 | Mar 31, 2024 | 40.07M | Jul 16, 2025 |
| FY2024 | Mar 31, 2023 | 40.07M | Aug 30, 2024 |
| FY2023 | Mar 31, 2022 | 38.92M | Jul 14, 2023 |
| FY2021 | Aug 31, 2021 | 34.87M | Oct 7, 2021 |
| FY2021 | Aug 31, 2020 | 34.49M | Oct 7, 2021 |
| FY2019 | Aug 31, 2019 | 20,570 | Dec 5, 2019 |
| FY2019 | Aug 31, 2018 | 20,570 | Dec 5, 2019 |
| FY2018 | Aug 31, 2017 | 6.02M | Nov 13, 2018 |
| FY2017 | Aug 31, 2016 | 6.02M | Dec 18, 2017 |